Recent trial findings of Junshi Biosciences' Toripalimab and Cetuximab combo for treating R/M-HNSCC were shared at the 38th annual SITC meeting in 2023.

Innovent Biologics reported two clinical research outcomes at the 2023 AAO annual meeting on Nov 6, 2023. These include the Phase 2 clinical data for IBI302, an anti-VEGF-anti-complement dual target drug for nAMD treatment, and Phase 1 clinical data for IBI324, an anti-VEGF-A/Ang-2 bispecific antibody for DME treatment.

Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.

HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.

Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.

The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.

The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.

Lirum Therapeutics announces encouraging results on LX-101, an innovative, clinical-phase targeted treatment, showing significant preliminary efficacy against children's sarcomas.

Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.

Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.

AceLink Therapeutics announced the initiation of AL01211 dosage for the first patient in its Phase 2 study for Fabry disease in China.

Nimbus Therapeutics, LLC has now shared preliminary findings from its ongoing Phase 1/2 trial of NDI-101150, an HPK1 small-molecule inhibitor.